Medicines optimisation: key therapeutic topics summarise the evidence-base on topics identified to support medicines optimisation, but are not formal NICE guidance.
These topics are selected and prioritised therapeutic areas where there are potential opportunities for maintaining or improving quality and improving value from our use of medicines. Releasing resources from one area of health care while maintaining or improving quality of care means those resources are available for use elsewhere, for example - the prescribing of innovative medicines.
Feedback from users suggests that in order for these topics to be considered in strategic priority plans, the topics would be better published in September.
September 2019 rapid update of medicines optimisation key therapeutic topics published
This update has retained 14 topics from March 2019:
- asthma: medicines safety priorities
- antipsychotics in people living with dementia
- antimicrobial stewardship: prescribing antibiotics
- type 2 diabetes mellitus: medicines optimisation priorities
- wound care products
- acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI
- multimorbidity and polypharmacy
- psychotropic medicines in people with learning disabilities whose behaviour challenges
- safer insulin prescribing
- medicines optimisation in chronic pain
- chemotherapy dose standardisation
- shared decision making
- suicide prevention: optimising medicines and reducing access to medicines as a means of suicide.
Two topics have been reincluded from the retired list:
- anticoagulants, including direct acting oral anticoagulants (DOACs). This topic was formerly known as anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs).
- lipid-modifying drugs.
The evidence context for all the current topics has been updated in the light of new guidance and important new evidence where appropriate.